Treatment of Still's Disease
IL-1 or IL-6 inhibitors should be initiated as early as possible when Still's disease is diagnosed, combined with short-term glucocorticoids that are rapidly tapered to avoid prolonged exposure. 1
First-Line Treatment Strategy
The 2024 EULAR/PReS guidelines fundamentally changed the treatment paradigm for Still's disease (encompassing both systemic juvenile idiopathic arthritis and adult-onset Still's disease, now unified under one name). Biologic DMARDs targeting IL-1 or IL-6 should be prioritized from diagnosis rather than relying on prolonged glucocorticoid monotherapy 1, 2.
Initial Therapy Components:
- IL-1 inhibitors (anakinra, canakinumab, rilonacept) OR IL-6 inhibitors (tocilizumab) as anchor therapy
- Glucocorticoids: High-dose (≥1 mg/kg/day prednisone equivalent) may be used initially for severe symptoms, but the goal is rapid tapering
- NSAIDs: Limited to symptomatic management during diagnostic workup only 1
The evidence strongly supports this approach: IL-1 and IL-6 inhibitors demonstrate the highest level of efficacy and safety with the most favorable risk-benefit ratio compared to all alternatives 2. Among IL-1 inhibitors, anakinra appears to have the most reassuring safety profile 1.
Treatment Targets and Timeline
The ultimate goal is drug-free remission, achieved through a treat-to-target approach with specific milestones 1:
- Day 7: Resolution of fever + CRP reduction >50%
- Week 4: No fever, active joint count reduced >50%, normal CRP, physician/patient global assessment <20/100
- Month 3: Clinically inactive disease with glucocorticoids <0.2 mg/kg/day (children) or <0.1 mg/kg/day (adults)
- Month 6: Clinically inactive disease WITHOUT glucocorticoids
Clinically inactive disease is defined as absence of Still's disease symptoms AND normal ESR or CRP. Remission requires maintaining clinically inactive disease for ≥6 months 1.
Choosing Between IL-1 and IL-6 Inhibitors
Start with either IL-1 or IL-6 inhibitor based on availability and clinical presentation 1. However:
- IL-1 inhibitors show lower rates of serious adverse events and infections compared to IL-6 inhibitors 1
- IL-6 inhibitors may be preferred for patients with prominent joint involvement 3
- Switch to the alternative class (IL-1 to IL-6 or vice versa) if inadequate response, intolerance, or treatment failure occurs 3, 4
Important caveat: IL-6 inhibitors may blunt CRP elevation, which can mask disease activity or complications like MAS 1.
Role of Conventional DMARDs
Conventional synthetic DMARDs have marginal efficacy and should NOT be first-line 2:
- Methotrexate: Failed to show superiority over placebo in the only RCT (even at ACR30 threshold) 1
- Consider methotrexate or other csDMARDs only in countries where IL-1/IL-6 inhibitors are unavailable 1, 5
- May serve as glucocorticoid-sparing agents in resource-limited settings, but biologics remain superior 1
Tapering and Discontinuation
Once clinically inactive disease is achieved:
- Maintain CID for 3-6 months WITHOUT glucocorticoids before considering biologic tapering 1
- Drug tapering or discontinuation may be considered in patients with sustained clinical and laboratory remission on IL-1 inhibitors 3
- Never use glucocorticoids to maintain disease control - if GC-dependence develops, add or switch biologics 1
Management of Macrophage Activation Syndrome (MAS)
MAS is a life-threatening complication requiring immediate recognition and treatment 1:
Suspect MAS with:
- Persistent fever
- Splenomegaly
- Elevated/rising ferritin
- Inappropriately low cell counts
- Abnormal liver function tests
- Coagulation abnormalities
- Elevated/rising triglycerides
MAS Treatment:
High-dose glucocorticoids PLUS anakinra, ciclosporin, and/or IFN-γ inhibitors (emapalumab) as initial combination therapy 1, 2. This represents the best available strategy despite limited data 2.
Refractory Disease
For patients failing initial IL-1 or IL-6 inhibitor:
- Switch to the alternative class (IL-1↔IL-6) 3, 4
- TNF inhibitors may be considered for prominent joint involvement after IL-1/IL-6 failure 3
- JAK inhibitors represent emerging options for later-line therapy 4, 6
Critical Pitfalls to Avoid
- Do NOT use prolonged glucocorticoid monotherapy - this causes severe side effects (growth retardation in children, metabolic syndrome in adults) without addressing underlying disease 1
- Do NOT delay biologic initiation - early use improves outcomes and limits glucocorticoid exposure 1
- Do NOT rely on methotrexate as primary therapy - evidence shows marginal efficacy 2
- Do NOT miss MAS - maintain high vigilance throughout disease course, even during remission 1